Tg Therapeutics (TGTX) Current Leases (2019 - 2026)

Tg Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Current Leases rose 63.26% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a 63.26% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, down 9.77% from the prior year.
• Current Leases grew to $1.8 million in Q1 2026 per TGTX's latest filing, from $1.0 million in the prior quarter.
• Across five years, Current Leases topped out at $1.8 million in Q1 2026 and bottomed at $1.0 million in Q4 2025.
• The 5-year median for Current Leases is $1.4 million (2023), against an average of $1.4 million.
• Across the five-year window, Current Leases decreased 19.99% in 2024 and jumped 63.26% in 2026, its largest moves.
• Year by year, Current Leases stood at $1.6 million in 2022, then declined by 8.54% to $1.4 million in 2023, then retreated by 19.99% to $1.2 million in 2024, then dropped by 9.77% to $1.0 million in 2025, then soared by 74.52% to $1.8 million in 2026.
• Per Business Quant, the three latest TGTX Current Leases figures stand at $1.8 million (Q1 2026), $1.0 million (Q4 2025), and $1.1 million (Q3 2025).